Vaccinex (VCNX)
(Delayed Data from NSDQ)
$4.75 USD
+0.20 (4.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $4.70 -0.05 (-1.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.75 USD
+0.20 (4.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $4.70 -0.05 (-1.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech
by Zacks Equity Research
Zacks.com featured highlights include: Bellicum Pharmaceuticals, Prometic Life Sciences, Vaccinex, Meridian Bioscience and 360 DigiTech
Bet on Rising P/E With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Implied Volatility Surging for Vaccinex (VCNX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vaccinex (VCNX) stock based on the movements in the options market lately.
Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Vaccinex, Inc. (VCNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vaccinex, Inc. (VCNX) delivered earnings and revenue surprises of 23.53% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Vaccinex, Inc. (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Vaccinex, Inc. (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bet on Rising Price-to-Earnings With 5 Top Stocks
by Sanghamitra Saha
Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.
Vaccinex (VCNX) Catches Eye: Stock Jumps 8.1%
by Zacks Equity Research
Vaccinex (VCNX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Vaccinex Inc (VCNX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vaccinex Inc (VCNX) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Vaccinex Inc (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Vaccinex Inc (VCNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
by Zacks Equity Research
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.